These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1915197)

  • 21. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1993 Apr; 33(4):350-6. PubMed ID: 8489205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
    Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
    Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms.
    Ondo WG; Sethi KD; Kricorian G
    Clin Neuropharmacol; 2007; 30(5):295-300. PubMed ID: 17909308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
    Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
    Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pattern of intracellular free amino acids in granulocytes from hemodialysis patients change to an oral protein supplement (granulocyte amino acids after protein in HD patients).
    Ivarsen P; Frystyk J; Pedersen EB
    Clin Nephrol; 1999 Aug; 52(2):110-8. PubMed ID: 10480222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods.
    Pincus JH; Barry K
    Neurology; 1988 Mar; 38(3):481-3. PubMed ID: 3126411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'On-off' phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma.
    Eriksson T; Granérus AK; Linde A; Carlsson A
    Neurology; 1988 Aug; 38(8):1245-8. PubMed ID: 3135513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does a low-protein diet help with Parkinson's?
    Yen PK
    Geriatr Nurs; 1990; 11(1):48. PubMed ID: 2153623
    [No Abstract]   [Full Text] [Related]  

  • 32. Parkinson's disease.
    Goldstein DJ
    Arch Neurol; 1988 Jul; 45(7):715-6. PubMed ID: 3390024
    [No Abstract]   [Full Text] [Related]  

  • 33. An international comparison of dietary protein consumption and mortality from Parkinson's disease.
    Coughlin SS; Pincus JH; Karstaedt P
    J Neurol; 1992 Apr; 239(4):236-7. PubMed ID: 1597693
    [No Abstract]   [Full Text] [Related]  

  • 34. Comments on the paper "High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. C.G. Coimbra and V.B.C. Junqueira. Brazilian Journal of Medical and Biological Research, 36: 1409-1417, 2003".
    Ferraz HB; Quagliato EA; Rieder CR; Silva DJ; Teive HA; Barbosa ER; Cardoso F; Limongi JC; Bezerra JM; Andrade LA; Allam N; Prado RC; Tomas V
    Braz J Med Biol Res; 2004 Sep; 37(9):1297-9; discussion 1299-302. PubMed ID: 15334194
    [No Abstract]   [Full Text] [Related]  

  • 35. Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.
    Wang L; Xiong N; Huang J; Guo S; Liu L; Han C; Zhang G; Jiang H; Ma K; Xia Y; Xu X; Li J; Liu JY; Wang T
    Front Aging Neurosci; 2017; 9():206. PubMed ID: 28701947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.
    Virmani T; Tazan S; Mazzoni P; Ford B; Greene PE
    J Clin Mov Disord; 2016; 3():8. PubMed ID: 27231577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dietary modification of Parkinson's disease.
    Croxson S; Johnson B; Millac P; Pye I
    Eur J Clin Nutr; 1991 May; 45(5):263-6. PubMed ID: 1915197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary method for reducing fluctuations in Parkinson's disease.
    Pincus JH; Barry KM
    Yale J Biol Med; 1987; 60(2):133-7. PubMed ID: 3577210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-lactalbumin combined with a regular diet increases plasma Trp-LNAA ratio.
    Beulens JW; Bindels JG; de Graaf C; Alles MS; Wouters-Wesseling W
    Physiol Behav; 2004 Jun; 81(4):585-93. PubMed ID: 15178151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study.
    Schindeler S; Ghosh-Jerath S; Thompson S; Rocca A; Joy P; Kemp A; Rae C; Green K; Wilcken B; Christodoulou J
    Mol Genet Metab; 2007 May; 91(1):48-54. PubMed ID: 17368065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.